click to watch our newest corporate video
Our vision is to empower humanity with a healthier future through transformative science. Our mission is to leverage the Trimer-Tag™ technology platform and our manufacturing capabilities for the discovery, development and commercialization of novel vaccines and biologic therapies.
With our leading COVID-19 vaccine candidate SCB-2019 (CpG 1018/Alum), we expect to commercialize one of the first protein-based COVID-19 vaccines enabling us to potentially help address the global shortage of COVID-19 vaccines.
The Trimer-Tag™ technology platform can trimerize any protein of interest and target a broad spectrum of naturally trimerization-dependent disease and biologic targets.
We have built our product pipeline by employing the Trimer-Tag™ technology platform.
Clover Provides Updates on COVID-19 Vaccine Commercial Launch and Strategic Priorities in 2023
Clover’s Vaccine Candidate Reduced Household Transmission of SARS-CoV-2 in Study Published in Clinical Infectious Diseases
Clover Provides Update on 2022 Corporate Milestones
Clover’s COVID-19 Vaccine Candidate Receives European Union GMP Certificate
